SleepTech start-up, SleepCogni, has raised £1.4m ($2m) to scale the business to commercialise into the US market, with the potential to help over 70m insomnia sufferers.
Chasnay Capital Investments has invested in UK-designed sleep therapy solution, SleepCogni.
The team behind UK-designed sleep therapy solution SleepCogni is celebrating after their device produced ‘extraordinary’ clinical trial results, significantly reducing clinical insomnia after just seven days.
SleepCogni has completed the medical device registration process with the US FDA as a Class II Biofeedback Device.
Dr Posner further strengthens SleepCogni’s existing medical & scientific advisory team with his world-renowned expertise in Cognitive Behavioral Therapy for Insomnia.
Sheffield-based SleepCogni has secured a further £575,000 through an interim fund-raising round, taking its total funding to date to £1.7m.
The Innovate UK government grant funds the collaboration between medical tech start-up SleepCogni and Sheffield Hallam University; recognising Sheffield as a leading science and technology hub.
Richard di Benedetto, the President of Aetna International, has pledged a six-figure investment of his own money as he becomes director and Chairman of SleepCogni.
An award-winning consumer personalised health device manufacturer specialising in sleep aid technologies is gearing up for growth following significant seed investment.